Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.34 |
| ▸ | GABRE | P78334 | 2/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.34 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24541229 | 0.80 | TDP1 (0.47) | KMT2AILKKDM4E | |
| SCHEMBL24468331 | 0.74 | IKBKE (0.32) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL29761649 | 0.73 | ILK (0.47) | KMT2AILKKDM4E | |
| SCHEMBL17514140 | 0.69 | GABRP (0.49) | HCAR2DAOGABRPGABRDGABRA1 | |
| SCHEMBL23757451 | 0.68 | PRMT5 (0.51) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL17514118 | 0.68 | GSK3A (0.51) | HCAR2DAOGABRPGABRDGABRA1 | |
| SCHEMBL24468454 | 0.67 | KMT2A (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27198277 | 0.67 | PI4KA (0.34) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL24468462 | 0.67 | MAP4K1 (0.35) | HCAR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL24468603 | 0.66 | KDM4E (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124442-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240092794-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11845760-B2 | PRMT5 inhibitors | AMGEN INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | US | disclosed |
| WO-2022132914-A1 | PRMTS INHIBITORS | AMGEN INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092794-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | HCAR2 4109/4885DAO 3023/4885GABRP 4402/4885 |
| US-20240124442-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | HCAR2 3688/4885DAO 1129/4885GABRP 4044/4885 |
| US-11845760-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | HCAR2 3945/4885DAO 3274/4885GABRP 4321/4885 |
| US-20220194955-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | HCAR2 4109/4885DAO 3023/4885GABRP 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.